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Background. Clostridioides difficile infection (CDI) might be complicated by the development of nosocomial bloodstream in-
fection (n-BSI). Based on the hypothesis that alteration of the normal gut integrity is present during CDI, we evaluated markers of 
microbial translocation, inflammation, and intestinal damage in patients with CDI.
Methods. Patients with documented CDI were enrolled in the study. For each subject, plasma samples were collected at T0 
and T1 (before and after CDI therapy, respectively), and the following markers were evaluated: lipopolysaccharide-binding protein 
(LPB), EndoCab IgM, interleukin-6, intestinal fatty acid binding protein (I-FABP). Samples from nonhospitalized healthy controls 
were also included. The study population was divided into BSI+/BSI- and fecal microbiota transplantation (FMT) +/FMT- groups, 
according to the development of n-BSI and the receipt of FMT, respectively.
Results. Overall, 45 subjects were included; 8 (17.7%) developed primary n-BSI. Markers of microbial translocation and intes-
tinal damage significantly decreased between T0 and T1, however, without reaching values similar to controls (P < .0001). Compared 
with BSI-, a persistent high level of microbial translocation in the BSI+ group was observed. In the FMT+ group, markers of micro-
bial translocation and inflammation at T1 tended to reach control values.
Conclusions. CDI is associated with high levels of microbial translocation, inflammation, and intestinal damage, which are 
still present at clinical resolution of CDI. The role of residual mucosal perturbation and persistence of intestinal cell damage in the 
development of n-BSI following CDI, as well as the possible effect of FMT in the restoration of mucosal integrity, should be further 
investigated.
Keywords.  Clostridioides difficile infection; microbial translocation; nosocomial bloodstream infection; LPS; I-FABP; fecal 
microbiota transplantation.
Clostridioides difficile infection (CDI) represents the leading 
cause of nosocomial diarrhea worldwide and is associated with 
growing rates of morbidity and mortality [1]. Apart from re-
currences, CDI is complicated by the development of nosoco-
mial bloodstream infections (n-BSIs) [2–4], with Candida spp. 
[2, 5, 6] and enteric bacteria as the leading pathogens [7–13]. 
Nevertheless, whether CDI predisposes subjects to subse-
quent BSI is still controversial, and neither the clinical link 
between CDI and n-BSI nor the exact pathogenesis has been 
demonstrated yet [11, 12]. Given that the observed n-BSIs have 
mostly been caused by fungi and bacteria belonging to enteric 
organisms, it was hypothesized that alteration of the normal gut 
integrity and microbial translocation from the gut to the sys-
temic circulation may play a role as pathogenetic triggers for the 
development of n-BSI [2].
Microbial translocation, defined as the migration of bacteria or 
their products from the gut to the extraintestinal space and even-
tually to the systemic circulation, might be promoted by increased 
intestinal permeability induced by disruption of intestinal epithe-
lial barrier function, intestinal bacterial overgrowth, and changes 
in the composition of bacterial microbes in the gut, all conditions 
present during CDI [13, 14]. Hence, the presence of circulating 
levels of lipopolysaccharide (LPS), a component of gram-nega-
tive bacterial cell membrane, induces production of host response 
molecules such as lipopolysaccharide-binding protein (LBP) and 
consumption of neutralizing antibodies against LPS endotoxin 
core antigen (antiendotoxin core antibody [EndoCab]).
Furthermore, C.  difficile toxins are responsible for damage 
to the intestinal epithelial cells, which represents an additional 
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key pathway implicated in the increased gut permeability and 
microbial translocation [15–17]. Fatty acid binding protein-2 
(FABP-2), also known as intestinal (I)-FABP, is present in ma-
ture enterocytes, and it is released as soon as cell membrane 
integrity is compromised and subsequently appears in the cir-
culation only after enterocyte injury [18, 19].
During the course of CDI, a significant increase in the levels 
of interleukin (IL)-6 has been reported [20], leading to the 
hypothesis that this cytokine plays a pivotal role in intestinal 
inflammation and systemic inflammatory response in CDI-
infected subjects [20].
Although biomarkers of microbial translocation, inflamma-
tion, and intestinal damage have been associated with multiple 
infective and noninfective diseases [13, 21], their role in CDI or 
in the pathogenesis of n-BSI after CDI is still unexplored.
Fecal microbiota transplantation (FMT) represents a highly 
effective strategy for the treatment of recurrent CDI [22, 23]. 
In addition, its possible role as an anti-infective therapeutic 
strategy has been recently hypothesized, likely through resto-
ration of the intestinal microbiota barrier and modulation of 
systemic inflammation [24].
On the basis of these observations, this study was under-
taken with the following objectives: (i) to evaluate the dynamic 
changes of circulating levels of LBP and EndoCab IgM (markers 
of microbial translocation), IL-6 (marker of inflammation), and 
I-FABP (marker of intestinal damage) in patients with CDI; (ii) 
to analyze whether these biomarkers are specifically modified 
in subjects who develop n-BSI within 60 days after the onset of 
CDI compared with those who do not develop n-BSI; and (iii) 
to investigate the effect of FMT on circulating levels of microbial 
translocation, inflammation, and intestinal damage biomarkers.
METHODS
Study Population
Over an 18-month period (January 2017–June 2018), patients 
with CDI hospitalized at the Azienda Ospedaliero-Universitaria 
Policlinico Umberto 1, Sapienza University (Rome), were en-
rolled in the study. Patients gave informed written consent, and 
the study protocol was approved by the local ethics committee. 
Exclusion criteria were age  <18  years, CDI suspected but not 
confirmed, patients not willing to participate at the study. 
Subjects were further divided into those developing primary 
n-BSI (BSI+) and those not developing primary n-BSI (BSI-) 
during the 60-day follow-up period. For the comparative anal-
ysis, subjects with nonprimary BSI were included in the BSI- 
group. In addition, patients receiving FMT as a CDI-specific 
therapy (FMT+) were compared with those being treated with 
conventional therapies (FMT-). Demographic, clinical, and mi-
crobiology data from all patients were recorded in an electronic 
database. Nonhospitalized healthy subjects (defined as controls, 
n = 15) matched for age and sex were also included. Each sub-
ject of the control group was asked whether he/she suffered 
from diarrhea or other chronic intestinal issues or new-onset 
symptoms in the 30  days before the blood collection. In the 
presence of at least 1 of these conditions, subjects were excluded 
from the control group.
Definitions
CDI infection, severe CDI, recurrence, and failure were defined 
according to guidelines [23, 25]. Treatment of CDI was chosen 
by the Infectious Diseases specialists according to severity of 
disease, previous number of CDI episodes, and risk factors 
for recurrence and included oral vancomycin (125  mg every 
6 hours for 10–14 days) ± intravenous metronidazole (500 mg 
every 6 hours for 10–14 days), fidaxomicin (200 mg every 12 
hours for 10 days), FMT.
According to the institutional protocol, FMT was performed 
only in subjects with recurrent (>1 episode) CDI, who were 
willing to receive FMT as part of CDI treatment, without im-
munosuppression, and in the absence of technical contraindica-
tions to the procedure, as determined by the Gastroenterology 
consultant. Each subject who received FMT was treated with a 
high dosage of oral vancomycin (ie, 500 mg every 6 hours) for 
4 days before the procedure, which was performed via retention 
enema. The reasons to exclude subjects from having FMT were 
an active BSI and being critically ill.
BSI was defined as a nosocomial infection (n-BSI) if it oc-
curred >48 hours after admission to the hospital [26]. Primary 
BSI was defined as BSI occurring in patients without a recog-
nized source of infection.
Markers of Microbial Translocation, Inflammation, and Intestinal Damage
For each subject, blood samples were collected at T0 (ie, before 
therapy or within 24 hours of the onset of CDI-specific therapy) 
and T1 (within 48 hours of the end of CDI-specific therapy), 
respectively.
In subjects who received FMT after a 4-day course of high-
dose oral vancomycin, T0 and T1 were defined as immediately 
before and 10 days after the FMT procedure, respectively, in ac-
cordance with the institutional protocol on blood collection in 
patients undergoing FMT.
Markers of microbial translocation (lipopolysacharide-
binding protein, Hycult Biotech; EndoCab IgM, Hycult 
Biotech), inflammation (IL-6, R&D Systems), and intestinal 
damage (intestinal fatty acid binding protein [I-FABP], R&D 
Systems) were evaluated using enzyme-linked immunosorbent 
assays in plasma. Briefly, after collection, blood was immedi-
ately centrifuged at 2000 rpm for 10 minutes and further frozen 
at –80°C until the assays were performed. LBP was expressed 
as ng/mL (sample diluted 1:2000), EndoCab IgM as MU/mL 
(sample diluted 1:100), IL-6 as pg/mL (sample undiluted), and 
I-FABP as pg/mL (sample diluted 1:5). Samples from healthy 
nonhospitalized subjects (controls, n = 15) matched for age and 
sex were also included and collected once.
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Statistical Analysis
Results were expressed as mean (±SD) or median (interquartile 
range [IQR]) and as percentages for continuous and categorical 
variables, respectively. Categorical variables were compared by 
using the X2 or Fisher exact test, as appropriate, whereas con-
tinuous data were analyzed with the Student t test and the non-
parametric Mann-Whitney test. Differences between T0 and 
T1 were evaluated by Wilcoxon test. Analysis of variance was 
used to compare the means of more than 2 groups. Statistical 
analyses were performed using GraphPad Prism, version 8, for 
Windows (Grafpad Software MacKiev).
RESULTS
Study Population
A total of 45 patients were included in the study. The mean age 
of the participants was 75 (±13.11) years, and one-third were 
females (n = 15) (Table 1). Two out of 45 (4.4%) were in the 
intensive care unit during admission, and 11/45 (24.4%) had 
central lines during hospitalization. The median time from the 
admission to CDI (IQR) was 12 (4–25) days. Specific therapy 
for CDI was oral vancomycin in 42/45 (93.3%), including those 
who received oral vancomycin before FMT (n = 6/45, 13.3%), 
intravenous metronidazole (always combined with oral van-
comycin) in 8/45 (17.7%), and fidaxomicin in 6/45 (13.3%). 
In particular, fidaxomicin was given as a firstline therapy in 2 
patients and after vancomycin failure in 4 subjects. As for the 
60-day outcomes, clinical cure was observed in 38/45 (84.4%), 
failure in 4/45 (8.9%), and recurrence in 3/45 (6.7%). N-BSI was 
observed in 10/45 (22.2%) subjects: Candida albicans, n  =  2; 
Gram-negatives, n = 4 (Klebsiella pneumoniae, n = 1; Escherichia 
coli, n = 1; Acinetobacter baumannii, n = 2); Enterococcus faecalis, 
n = 1; C. albicans, K. pneumoniae, E. faecalis, n = 1; methicillin-
resistant Staphylococcus aureus (MRSA), n = 1; Staphylococcus 
hominis, n = 1. Among the n-BSI, 8 were considered primary 
BSIs, and 2 were attributable to secondary bacteremia and/or 
Table 1. Characteristics of the General Population
Population Global (n = 45) BSI+ a (n = 8) BSI- (n = 37)
Age, mean ± SD, y 75 ± 13.11 70 ± 14.26 77 ± 9.75
Sex (M/F) 30/15 6/2 24/5
Risk factors, No. (%)    
Previous hospitalization 40 (88.8) 7 (87.5) 33 (89.1)
Previous antibiotics 37 (82.2) 7 (87.5) 30 (81)
PPI 30 (66.6) 7 (87.5) 23 (62.1)
Beta-blockers 14 (31.1) 4 (50) 10 (27)
Major surgery 2 (4.4) 1 (12.5) 1 (2.7)
Immunodepression 5 (11.1) 2 (25) 3 (8.1)
ICU during admission, No. (%) 2 (4.4) 1 (12.5) 1 (2.7)
Central lines during hospitalization, No. (%) 11 (24.4) 2 (25) 9 (24.3)
Time from the admission to CDI, median (IQR), d 12 (4–25) 16.5 (4.5–28) 12 (1.5–23)
Clinical presentation, No. (%)    
Diarrhea 45 (100) 8 (100) 37 (100)
Fever 13 (28.8) 1 (12.5) 12 (32.4)
Leukocytosis 15 (33.3) 2 (25) 13 (35.1)
Severity of disease, No. (%)    
Mild–moderate 33 (73.3) 6 (75) 27 (72.9)
Severe 12 (26.6) 2 (25) 10 (27.1)
Ribotype, No. (%)    
027 8 (17.7) 1 (12.5) 7 (18.9)
078 3 (6.6) 0 (0) 3 (8.1)
Therapy, No. (%)    
Vancomycin 42 (93.3) 7 (87.5) 36 (97.2)
Metronidazole 8 (17.7) 0 (0) 8 (21.6)
Fidaxomicin 6 (13.3) 1 (12.5) 5 (13.5)
FMT 6 (13.3) 0 (0) 6 (16.2)
Outcome, 60 d, No. (%)    
Clinical cure 38 (84.4) 7 (87.5) 31 (83.8)
Failure 4 (8.9) 0 (0) 4 (10.8)
Relapse 3 (6.7) 1 (12.5) 2 (5.4)
Abbreviations: BSI, bloodstream infection; CDI, Clostridioides difficile infection; FMT, fecal microbiota transplantation; ICU, intensive care unit; IQR, interquartile range; PPI, proton pump 
inhibitor. 
aOnly primary BSIs, defined as BSIs occurring in patients without a recognized source of infection, were considered for the comparison of microbial translocation, inflammation, and intes-
tinal damage markers between subjects developing n-BSI and subjects not developing n-BSI.
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caused by microorganisms not normally present in the gut; 
thus, only 8/45 (17.7%) subjects were included in the BSI+ 
group, whereas subjects with nonprimary BSI were included in 
the non-BSI population (Supplementary Table 1). The median 
time from CDI and the development of primary n-BSI (IQR) 
was 20.5 (9.75–35.75) days (Supplementary Table 1). Among 
subjects with severe CDI (12/45, 26.6%), 2 (16.6%) developed 
primary n-BSI, whereas in nonsevere CDI (33/45, 73.4%) pri-
mary n-BSI was observed in 6 patients (18.2%).
In subjects developing primary n-BSI (n  =  8), the me-
dian time between the beginning and end of CDI-specific 
therapy (IQR) was 14 (12.5–14) days; 1 subject (12.5%) re-
ceived fidaxomicin after vancomycin treatment failure, and 
1 (12.5%) subject received fidaxomicin as firstline therapy 
(Supplementary Table 1). In the BSI- group (n = 37), the me-
dian time between the beginning and end of therapy (IQR) was 
13 (9–14) days; 3 subjects (6.6%) received fidaxomicin after 
vancomycin treatment failure, and 1 subject (2.7%) received 
fidaxomicin as firstline therapy. No patients receiving FMT de-
veloped a subsequent n-BSI.
A total of 15 controls were also included in the study. The 
mean age of the controls was 71 (±15.56) years, and 4/15 
(26.6%) were females. None of the controls suffered from diar-
rhea or other chronic intestinal issues or new-onset symptoms 
in the 30 days before blood collection.
Markers of Microbial Translocation, Inflammation, and Intestinal Damage 
During the Course of CDI
Overall, a high degree of microbial translocation, inflamma-
tion, and intestinal damage was observed during the course of 
CDI, which lowered from the beginning to the end of therapy 
but did not reach values similar to controls.
In particular, the median LPB plasma levels at T0 were signif-
icantly higher than those of controls (29 960 vs 14 357 ng/mL; 
P ≤ .0001). At the end of therapy (T1), there was a significant 
reduction in LPB levels (21 160 ng/mL; P <  .0002), but values 
were still not comparable to controls (Figure 1A).
When we assessed the degree of consumption of neutral-
izing antibodies against LPS endotoxin core antigen (EndoCab 
IgM) during the course of CDI, the median values at T0 were 
significantly lower than those of controls (30.31 vs 173.4 MU/
mL; P  <  .0001). Although there was a significant increase at 
T1 (31.72 MU/mL; P = .0103), EndoCab IgM values remained 
lower than those observed in controls (Figure 1 B).
The median circulating levels of IL-6 at T0 were signifi-
cantly higher than in controls (37.09 vs 1.82 pg/mL; P < .0001). 
Although a reduction of IL-6 levels was observed at the end of 
therapy (26.6 pg/mL; P  =  .16), values remained considerably 
higher than those of controls (Figure 1 C).
As for the degree of intestinal damage occurring during the 
course of CDI, the median values were similarly elevated at T0 
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Figure 1. Markers of microbial translocation (A and B), inflammation (C), and intestinal damage (D) in patients (n = 45) during the course of Clostridioides difficile infection (CDI). 
Horizontal lines and whiskers represent median and the 25th and 75th percentile values, respectively. *P < .01; **P < .001. Abbreviations: EndoCab IgM, antiendotoxin core antibody 
IgM; I-FABP, intestinal fatty acid binding protein; LBP, lipopolysaccharide-binding protein; T0, at the beginning of CDI-specific therapy; T1, at the end of CDI-specific therapy.
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and T1 (1171 and 1002 pg/mL), respectively, and were signifi-
cantly higher than those of controls (P < .0001) (Figure 1 D).
Microbial Translocation, Inflammation, and Intestinal Damage in Patients 
Developing BSI During the Follow-up Period
Markers of Microbial Translocation (LBP and EndoCab IgM)
The extent of microbial translocation, expressed by high levels of 
LBP and low levels of EndoCab IgM, did not differ between the 
BSI+ and BSI- groups at the beginning and at the end of therapy. 
Interestingly, although microbial translocation remained con-
stantly high between the beginning and end of therapy in 
subjects developing primary n-BSI (from 27 955 to 24 175 ng/
mL and from 42.78 to 31.43 MU/mL for LBP and EndoCab 
IgM, respectively), it showed a statistically significant reduc-
tion in subjects not developing BSI (from 30 960 to 20 950 ng/
mL; P = .0002; and from 28.86 to 34.46 MU/mL; P = .0006; for 
LBP and EndoCab IgM, respectively). Both groups at the end of 
therapy showed a significantly higher level of microbial translo-
cation than controls (Figure 2A, B).
Marker of Inflammation (IL-6)
No differences were observed between the 2 groups as for me-
dian IL-6 circulating levels at the beginning and end of the 
therapy. Although both groups showed a decrease in IL-6 values 
from the beginning to the end of therapy (from 35.16 to 24.68 
pg/mL in BSI+ and from 39.01 to 29.49 pg/mL in BSI-), this 
difference was not significant. However, at the end of therapy, 
both groups of subjects exhibited a higher grade of inflamma-
tion than controls (Figure 2 C).
Intestinal Damage (I-FABP)
The extent of intestinal damage during the course of CDI 
was constantly high and did not differ between the 2 groups. 
Interestingly, the intestinal damage tended to increase between 
the beginning and the end of therapy in subjects developing pri-
mary n-BSI (from 754.5 to 1002 pg/mL; P =  .48), whereas in 
subjects not developing n-BSI a decrease in circulating I-FABP 
levels was observed (from 1171 to 1002 pg/mL; P = .53). At the 
end of therapy, the levels of I-FABP were significantly higher 
than those of controls in both groups (Figure 2 D).
Markers of Microbial Translocation, Inflammation, and Intestinal Damage 
in Patients Receiving FMT as a CDI-Specific Therapy
Microbial Translocation (LBP and EndoCab IgM)
Subjects receiving fecal microbiota transplantation had a lower 
level of microbial translocation than those treated with other 
therapies, both at the beginning and at the end of therapy. 
Notably, at the end of therapy subjects in the FMT+ group 
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Figure 2. Markers of microbial translocation (A and B), inflammation (C), and intestinal damage (D) in patients who developed BSI (n = 8) after Clostridioides difficile 
infection (CDI), in comparison with subjects not who did not develop BSI (n = 37). Horizontal lines and whiskers represent median and the 25th and 75th percentile values, 
respectively. *P < .01; **P < .001. Abbreviations: EndoCab IgM, antiendotoxin core antibody IgM; I-FABP, intestinal fatty acid binding protein; LBP, lipopolysaccharide-binding 
protein; T0, at the beginning of CDI-specific therapy; T1, at the end of CDI-specific therapy.
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tended to have LBP circulating values similar to those observed 
in controls (P =  .1), whereas subjects treated with other ther-
apies maintained a significantly higher degree of LBP than con-
trols (P < .0001). As for the levels of circulating EndoCab IgM, 
both groups had values significantly lower than controls (Figure 
3A, B).
Inflammation (IL-6)
Median circulating IL-6 levels were significantly lower in 
subjects receiving fecal microbiota transplantation than those 
treated with other therapies at the beginning and at the end of 
therapy (8.32 vs 29.01 pg/mL and 5.21 vs 30.66 pg/mL, respec-
tively), with a statistically significant difference especially at the 
end of treatment (P  =  .0005). Interestingly, after fecal micro-
biota transplantation, the degree of inflammation was similar 
to that observed in controls (5.21 vs 1.82 pg/mL) (Figure 3 C).
Intestinal Damage (I-FABP)
The extent of intestinal damage during the course of CDI did 
not differ between the 2 groups. At the end of therapy, the levels 
I-FABP were significantly higher than those of controls in both 
groups (Figure 3 D).
The distribution of markers of microbial translocation, in-
flammation, and intestinal damage in patients experiencing 
failure (n = 4) and CDI recurrence (n = 3) at the 60-day fol-
low-up is shown in Supplementary Figures 1 and 2, respectively.
Correlations Among Markers of Microbial Translocation, Inflammation, 
and Intestinal Damage During the Course of CDI
The extent of microbial translocation (expressed as high LBP 
and low EndoCab IgM levels, respectively) correlated with the 
degree of systemic inflammation, especially at T0, whereas a 
higher level of IL-6 at the beginning of therapy negatively in-
fluenced the levels of neutralizing antibodies against LPS endo-
toxin core antigen at the end of therapy. Furthermore, the high 
levels of microbial translocation, inflammation, and intestinal 
damage at the onset of CDI positively correlated with the degree 
of these biomarkers at the end of CDI-specific therapy (Table 2).
DISCUSSION
CDI is the most common cause of nosocomial infectious diar-
rhea in hospitalized patients, with up to 35% of patients having 
recurrent infections and a non-negligible percentage of subjects 
developing n-BSI [1]. However, even though there is increasing 
evidence that CDI might be complicated by n-BSI, with Candida 
spp. and enteric bacteria as the leading pathogens [2, 3, 5], the 
possible link between these infections is still a matter of debate 
[11, 12]. Indeed, from a clinical point of view, being aware of the 
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Figure 3. Markers of microbial translocation (A and B), inflammation (C), and intestinal damage (D) in patients who received FMT (n = 6) as a Clostridioides difficile infection 
(CDI)–specific therapy, in comparison with subjects who did not receive FMT (n = 39). Horizontal lines and whiskers represent median and the 25th and 75th percentile values, 
respectively. *P < .01; **P < .001. Abbreviations: EndoCab IgM, antiendotoxin core antibody IgM; FMT, fecal microbiota transplantation; I-FABP, intestinal fatty acid binding 
protein; LBP, lipopolysaccharide-binding protein; T0, at the beginning of CDI-specific therapy; T1, at the end of CDI-specific therapy.
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possibility of this coinfection, physicians might be more vigilant 
for early recognition and treatment of n-BSI, especially during 
the first 4 weeks after CDI diagnosis, as this complication is as-
sociated with high mortality rates [2]. On the other hand, from 
a pathogenetic standpoint, it appears essential to demonstrate 
whether there is a condition predisposing to the passage of bac-
teria or fungi from the gut into the systemic circulation, with 
the hypothesized mechanism residing mostly on the possible 
alteration of mucosal integrity occurring during CDI.
Microbial translocation, which is defined as the passage of 
indigenous bacteria from the gastrointestinal tract through the 
lamina propria to the mesenteric lymph nodes and other or-
gans, occurs as a consequence of the perturbation of the normal 
mucosal integrity, and the extent of microbial translocation rate 
differs between microorganisms, with gram-negative enteric 
bacilli translocating more than gram-positive and obligately an-
aerobic bacteria, respectively [14, 27–29].
Based on these considerations, the present study was aimed 
at examining whether microbial translocation, inflammation, 
and intestinal damage biomarkers are altered in subjects with 
CDI and, accordingly, revealing whether there is an increased 
susceptibility of patients to subsequent n-BSI. Indeed, here we 
have demonstrated for the first time that CDI is characterized 
by high levels of microbial translocation, inflammation, and 
intestinal damage and that the residual high mucosal pertur-
bation and intestinal cell damage are still present at clinical res-
olution of the infection.
In fact, at the beginning of CDI (ie, before or within 24 hours 
of the onset of CDI-specific therapy), high levels of microbial 
translocation, inflammation, and intestinal damage were ob-
served, which lowered at the end of treatment. However, these 
biomarkers, although significantly reduced from the beginning 
to the end of therapy, did not reach values comparable to those 
of controls, thus demonstrating that mucosal perturbation and 
intestinal damage persist despite the clinical resolution of CDI.
Apart from subjects with CDI, in critically ill patients the 
development of a systemic inflammatory response related to 
surgery, ischemia-riperfusion syndrome after major (ie, cardio-
thoracic) surgeries, and the use of extracorporeal circulation, all 
conditions related to a lower rate of intestinal perfusion, have 
been associated with a certain extent of microbial translocation, 
suggesting that microbial translocation does not occur infre-
quently and might be involved in the pathogenesis of infective 
and noninfective conditions [30–32].
When considering the microbial translocation, inflamma-
tion, and intestinal damage levels in subjects developing n-BSI 
in the 60  days after CDI, we noted that patients in the BSI+ 
group maintained a high degree of mucosal alteration and mi-
crobial translocation, which appeared to persist to a greater ex-
tent than those in the BSI- group.
Our findings are in line with recent murine models sug-
gesting that the loss of barrier function during CDI predisposes 
to bacterial translocation and systemic dissemination [33–36], 
whereas noninfective gut disorders such as inflammatory bowel 
disease and antibiotic-induced diarrhea have been associated 
with anaerobic and Klebsiella oxytoca bacteremia [37, 38], re-
spectively, indicating microbial translocation and intestinal 
damage as the common causal mechanisms [39].
With regard to the intestinal damage, an increase of I-FABP 
from the beginning to the end of therapy in the BSI+ group 
has been demonstrated, although it was not statistically sig-
nificant [16, 40]; if confirmed in future better-powered co-
horts, this might indicate that the CD-induced cell damage 
still present even at the end of therapy might favor the passage 
Table 2. Correlation Analyses of MT, IN, and ID Biomarkers in 45 Patients During the Course of CDI
LBP T0
EndoCab IgM 
T0 IL-6 T0
I-FABP 
T0
LBP  
T1
EndoCab IgM 
T1
IL-6  
T1
I-FABP  
T1 CRP CRE
LBP   
T0
– –0.23  
0.11
0.52  
0.0002
0.0128 
0.9392
0.42  
0.004
–0.18  
0.22
0.12  
0.43
0.10  
0.54
0.18  
0.25
–0.30  
0.05
EndoCab IgM T0 – – –0.38  
0.01
0.06  
0.71
–0.15 
0.32
0.82  
<0.0001
–0.13  
0.39
0.02  
0.86
–0.04 
0.77
0.17  
0.28
IL-6   
T0
– – – –0.05  
0.75
0.13  
0.37
–0.40  
0.006
0.28  
0.06
 0.04  
0.8
–0.02 
0.9
I-FABP T0 – – – – 0.12  
0.45
–0.17  
0.29
–0.04  
0.77
0.71  
<0.0001
0.04  
0.8
–0.30 
0.09
LBP   
T1
– – – – – 0.07  
0.63
0.60  
<0.0001
–0.06  
0.70
0.02  
0.89
0.03  
0.85
EndoCab IgM T1 – – – – – – –0.19  
0.20
–0.21  
0.21
–0.08 
0.6
0.15  
0.35
IL-6   
T1
– – – – – – – –0.08  
0.61
0.03  
0.84
–0.10 
0.54
I-FABP T1 – – – – – – – – 0.10  
0.58
–0.31 
0.09
The first lines are Spearman correlation coefficient values; the second lines are P values. Values in bold represent statistically significant correlations (P < .05).
Abbreviations: CDI, Clostridioides difficile infection; CRE, creatinine; CRP, C-reactive protein; EndoCab IgM, antiendotoxin core antibody IgM; I-FABP, intestinal fatty acid binding protein; ID, 
intestinal damage; IN, inflammation; LBP, lipopolysaccharide-binding protein; MT, microbial translocation; T0, at the beginning of CDI-specific therapy; T1, at the end of CDI-specific therapy. 
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of microorganisms through an impaired intestinal barrier. In 
contrast, the observed high level of intestinal damage even in 
the BSI- group is possibly explained by the fact that oral vanco-
mycin, which possesses an intrinsic toxicity toward enterocytes, 
has been given in almost all patients with CDI [41–43].
CDI toxins activate immune cells to produce pro-
inflammatory cytokines such as TNF-alpha and IL-6, leading 
to a robust inflammatory response, which represents the hall-
mark of CDI pathogenesis [15]. In our cohort, both the BSI+ 
and BSI- groups showed higher levels of IL-6 than controls at 
the end of therapy, suggesting that the degree of inflammation 
might not be involved in the development of n-BSI. In contrast, 
the high level of inflammation at the beginning of CDI-specific 
therapy might influence the recovery rate of neutralizing anti-
bodies against LPS endotoxin core antigen at the clinical resolu-
tion of CDI, as highlighted by the correlation analyses (Table 2).
It should be acknowledged that our study cohort is too small 
to reach a definite conclusion on the attractive hypothesis 
that persistent gut permeability and intestinal damage might 
increase the risk of BSI. Therefore, the role of residual mucosal 
perturbation and the persistence of intestinal cell damage in the 
development of n-BSI following CDI should be further investi-
gated in the future.
An additional hallmark of the present study resides in the 
evaluation of the degree of microbial translocation, inflamma-
tion, and intestinal damage biomarkers in patients receiving 
FMT as a targeted therapy for CDI. Although only 6 patients 
have been treated with FMT, we have shown that FMT+ subjects 
tended to have levels of LBP and circulating neutralizing anti-
bodies against LPS endotoxin core antigen similar to those 
observed in controls. Similarly, circulating IL-6 levels were sig-
nificantly lower in FMT+ than in FMT- subjects, and that ef-
fect was more evident at the end of treatment. In contrast, the 
degree of intestinal damage did not differ between the 2 groups 
and remained persistently high. The low levels of microbial 
translocation and inflammation observed immediately before 
FMT in subjects belonging to the FMT group might have been 
influenced by the effect of oral vancomycin therapy, which was 
administered for 4 days before the procedure and, accordingly, 
might not reflect the real values of these markers at the begin-
ning of CDI. On the other hand, the results at the end of therapy 
(10 days after the FMT) might reflect the effect of FMT on these 
biomarkers. In fact, for unlikely subjects not receiving FMT but 
receiving oral therapies (ie, vancomycin or fidaxomicin), values 
of microbial translocation and inflammation 10 days after FMT 
tended to be more similar to those obtained in controls. This 
was especially true for microbial translocation and inflamma-
tion markers, whereas I-FABP did not differ between the FMT+ 
and FMT- groups and did not tend to reach values similar to 
controls. The last result might be easily explained with the de-
scribed toxicity of oral vancomycin on intestinal cells. Taken to-
gether, these findings show that, compared with traditional oral 
therapies for CDI, the administration of FMT might be able to 
restore the degree of microbial translocation and inflammation 
in subjects with CDI.
Overall, our findings highlight the deep and mutual relation-
ship that exists between the extent of inflammation, intestinal 
damage, and gut mucosal perturbation during the course of 
CDI. Whether the residual degree of microbial translocation 
and CD-induced intestinal damage possess a pathogenetic role 
in the development of n-BSI following CDI or whether FMT 
has a protective effect on n-BSI has yet to be demonstrated.
As for clinical implications, the results of the present study 
highlight the concept that, despite clinical resolution of CDI, 
there is still a non-negligible degree of alteration of gut mucosal 
integrity, possibly leading to a subsequent passage of micro-
organisms into the systemic circulation. To this end, markers of 
microbial translocation, inflammation, and intestinal damage 
might represent useful tools for the monitoring of mucosal in-
tegrity in patients with CDI. Furthermore, clinicians should con-
sider FMT a reliable option for the treatment of CDI, not only 
due its well-known efficacy in lowering the rate of recurrences 
[22], but also because the administration of FMT might be able 
to restore the degree of mucosal permeability and inflammation.
The present investigation has several limitations, such as (i) 
low number of patients; (ii) evaluation of markers of microbial 
translocation, inflammation, and intestinal damage before and 
immediately after CDI-specific therapy, with no information re-
garding the time to obtaining mucosal integrity restoration after 
therapy; and (iii) the cohort of subjects with primary n-BSI was 
not sufficiently powered to demonstrate that the development 
of n-BSI correlates to any of the observed biomarkers.
CONCLUSIONS
In conclusion, it is herein demonstrated for the first time that 
CDI is associated with an elevation in markers of microbial 
translocation, inflammation, and epithelial damage, which per-
sists despite the clinical resolution of CDI. Further investiga-
tions are needed to test the hypothesis that the development of 
n-BSI is associated with gut mucosal permeability and intestinal 
damage following CDI.
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